Literature DB >> 26810039

Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine Efficacy.

Roberto De Pascalis1, Lara Mittereder2, Nikki J Kennett2, Karen L Elkins1.   

Abstract

We previously identified potential correlates of vaccine-induced protection against Francisella tularensis using murine splenocytes and further demonstrated that the relative levels of gene expression varied significantly between tissues. In contrast to splenocytes, peripheral blood leukocytes (PBLs) represent a means to bridge vaccine efficacy in animal models to that in humans. Here we take advantage of this easily accessible source of immune cells to investigate cell-mediated immune responses against tularemia, whose sporadic incidence makes clinical trials of vaccines difficult. Using PBLs from mice vaccinated with F. tularensis Live Vaccine Strain (LVS) and related attenuated strains, we combined the control of in vitro Francisella replication within macrophages with gene expression analyses. The in vitro functions of PBLs, particularly the control of intramacrophage LVS replication, reflected the hierarchy of in vivo protection conferred by LVS-derived vaccines. Moreover, several genes previously identified by the evaluation of splenocytes were also found to be differentially expressed in immune PBLs. In addition, more extensive screening identified additional potential correlates of protection. Finally, expression of selected genes in mouse PBLs obtained shortly after vaccination, without ex vivo restimulation, was different among vaccine groups, suggesting a potential tool to monitor efficacious vaccine-induced immune responses against F. tularensis. Our studies demonstrate that murine PBLs can be used productively to identify potential correlates of protection against F. tularensis and to expand and refine a comprehensive set of protective correlates.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26810039      PMCID: PMC4807470          DOI: 10.1128/IAI.01348-15

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Studies on the variation of Bacterium tularense.

Authors:  H T EIGELSBACH; W BRAUN; R D HERRING
Journal:  J Bacteriol       Date:  1951-05       Impact factor: 3.490

Review 2.  Subpopulations of Francisella tularensis ssp. tularensis and holarctica: identification and associated epidemiology.

Authors:  Jeannine M Petersen; Claudia R Molins
Journal:  Future Microbiol       Date:  2010-04       Impact factor: 3.165

3.  Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis.

Authors:  D M Waag; K T McKee; G Sandstrom; L L Pratt; C R Bolt; M J England; G O Nelson; J C Williams
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

4.  Measurement of macrophage-mediated killing of intracellular bacteria, including Francisella and mycobacteria.

Authors:  Karen L Elkins; Siobhán C Cowley; J Wayne Conlan
Journal:  Curr Protoc Immunol       Date:  2011-04

Review 5.  Tularemia vaccines: recent developments and remaining hurdles.

Authors:  J Wayne Conlan
Journal:  Future Microbiol       Date:  2011-04       Impact factor: 3.165

6.  Immunity against Francisella tularensis in northern Finland.

Authors:  P Koskela; E Herva
Journal:  Scand J Infect Dis       Date:  1982

7.  Live vaccine strain of Francisella tularensis: infection and immunity in mice.

Authors:  A H Fortier; M V Slayter; R Ziemba; M S Meltzer; C A Nacy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

Review 8.  Live attenuated tularemia vaccines: recent developments and future goals.

Authors:  Mark E Marohn; Eileen M Barry
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

Review 9.  Transcriptional profiling of vaccine-induced immune responses in humans and non-human primates.

Authors:  I-Ming Wang; Andrew J Bett; Razvan Cristescu; Andrey Loboda; Jan ter Meulen
Journal:  Microb Biotechnol       Date:  2011-11-22       Impact factor: 5.813

10.  Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model.

Authors:  Magali Matsumiya; Iman Satti; Agnieszka Chomka; Stephanie A Harris; Lisa Stockdale; Joel Meyer; Helen A Fletcher; Helen McShane
Journal:  J Infect Dis       Date:  2014-11-07       Impact factor: 5.226

View more
  10 in total

1.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

Review 2.  The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Authors:  Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2020-02-11       Impact factor: 3.131

3.  A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis.

Authors:  Roberto De Pascalis; Andrew Hahn; Helen M Brook; Patrik Ryden; Nathaniel Donart; Lara Mittereder; Blake Frey; Terry H Wu; Karen L Elkins
Journal:  PLoS One       Date:  2018-05-25       Impact factor: 3.240

Review 4.  A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens.

Authors:  A Abraham; G Ostroff; S M Levitz; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2019-09-12       Impact factor: 4.330

5.  Working correlates of protection predict SchuS4-derived-vaccine candidates with improved efficacy against an intracellular bacterium, Francisella tularensis.

Authors:  Roberto De Pascalis; Blake Frey; Helen M Rice; Varunika Bhargava; Terry H Wu; Ross L Peterson; J Wayne Conlan; Anders Sjöstedt; Karen L Elkins
Journal:  NPJ Vaccines       Date:  2022-08-17       Impact factor: 9.399

6.  Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.

Authors:  Katherine J O'Malley; Jennifer D Bowling; Elizabeth Stinson; Kelly S Cole; Barbara J Mann; Prachi Namjoshi; Karsten R O Hazlett; Eileen M Barry; Douglas S Reed
Journal:  PLoS One       Date:  2018-10-22       Impact factor: 3.240

7.  The Diversity Outbred Mouse Population Is an Improved Animal Model of Vaccination against Tuberculosis That Reflects Heterogeneity of Protection.

Authors:  Sherry L Kurtz; Amy P Rossi; Gillian L Beamer; Dan M Gatti; Igor Kramnik; Karen L Elkins
Journal:  mSphere       Date:  2020-04-15       Impact factor: 4.389

8.  Novel Transcriptional and Translational Biomarkers of Tularemia Vaccine Efficacy in a Mouse Inhalation Model: Proof of Concept.

Authors:  Qing Yan Liu; Sonia Leclerc; Youlian Pan; Ziying Liu; Felicity Stark; Joseph Wayne Conlan
Journal:  Microorganisms       Date:  2021-12-26

9.  The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection.

Authors:  Lauren E Shoudy; Prachi Namjoshi; Gabriela Giordano; Sudeep Kumar; Jennifer D Bowling; Carl Gelhaus; Eileen M Barry; Allan J Hazlett; Brian A Hazlett; Kristine L Cooper; Phillip R Pittman; Douglas S Reed; Karsten R O Hazlett
Journal:  Pathogens       Date:  2021-12-20

10.  Immune lymphocytes halt replication of Francisella tularensis LVS within the cytoplasm of infected macrophages.

Authors:  Mary Katherine Bradford; Karen L Elkins
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.